Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 8/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2350757 | 0.91 | KDR (0.46) | P2RY1MAPTKDRABL1GAA | |
| SCHEMBL2352600 | 0.90 | KDR (0.45) | P2RY1MAPTKDRABL1GAA | |
| SCHEMBL2347054 | 0.89 | P2RY1 (0.46) | P2RY1MAPTKDRABL1GAA | |
| SCHEMBL2345032 | 0.89 | P2RY1 (0.44) | P2RY1MAPTKDRABL1GAA | |
| SCHEMBL2351862 | 0.89 | ABCB1 (0.45) | P2RY1MAPTKDRABL1GAA | |
| SCHEMBL1549375 | 0.88 | P2RY1 (0.46) | P2RY1MAPTKDRABL1EPHX2 | |
| SCHEMBL2341901 | 0.88 | MAPT (0.45) | P2RY1MAPTKDRABL1GAA | |
| SCHEMBL2347022 | 0.87 | KDR (0.44) | P2RY1MAPTKDRABL1KCNH2 | |
| SCHEMBL2347697 | 0.87 | DHODH (0.48) | P2RY1MAPTKDRABL1EPHX2 | |
| SCHEMBL2348490 | 0.87 | P2RY1 (0.47) | P2RY1MAPTKDRABL1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314585-B1 | Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC (JP) | 2012-09-12 | — | — | EP | claimed |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | claimed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008292-B2 | Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035882-A1 | CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY | TRPV1, TRPV2, TRPA1 | P2RY1 124/4885MAPT 4135/4885KDR 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.